|
|
Volumn 171, Issue 9, 2004, Pages 1027-1028
|
|
Rofecoxib (Vioxx) voluntarily withdrawn from market.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LACTONE;
ROFECOXIB;
SULFONE;
ARTICLE;
CEREBROVASCULAR ACCIDENT;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DRUG CONTROL;
DRUG INDUSTRY;
HEART INFARCTION;
HUMAN;
MORTALITY;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
SURVIVAL;
UNITED STATES;
CEREBROVASCULAR ACCIDENT;
DRUG AND NARCOTIC CONTROL;
DRUG INDUSTRY;
HUMANS;
LACTONES;
MYOCARDIAL INFARCTION;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
SULFONES;
SURVIVAL ANALYSIS;
UNITED STATES;
|
|
EID: 11244249628
PISSN: 08203946
EISSN: None
Source Type: Journal
DOI: 10.1503/cmaj.1041606 Document Type: Article |
|
Times cited : (120)
|
|
References (0)
|
